Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 149-153

  Masi, Laura ^a   Franceschelli, Francesco ^a   Leoncini, Gigliola ^a   Gozzini, Alessia ^a   Rigante, Donato ^b   La Torre, Francesco ^c   Matucci Cerinic, Marco ^d   Brandi, Maria Luisa ^a   Falcini, Fernanda ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Rheumatology Section   (Italy)

Author keywords

Coronary artery disease; Fibroblast growth factor 23; Kawasaki disease

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY ANOMALY; CORONARY ARTERY DILATATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SCHOOL CHILD;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CORONARY ANEURYSM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFANT; LOGISTIC MODELS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK FACTORS; UP-REGULATION;

EID: 84874903188     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. FALCINI F, CAPANNINI S, RIGANTE D: Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J 2011; 9: 17.
2. MATSUBARA T, FARUKAWA S, YABUTA K: Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56: 29-36.
3. HIRAO J, HIBI S, ANDOH T, ICHIMURA T: High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997; 112: 152-6.
4. MIURA M, GARCIA FL, CRAWFORD SE, ROWLEY AH: Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr Infect Dis 2004; 23: 931-6.
5. RIGANTE D, VALENTINI P, RIZZO D et al.: Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int 2010; 30: 841-6.
6. SENZAKI H: Long-term outcome of Kawasaki disease. Circulation 2008; 118: 2763-72.
7. MCCRINDLE WB: Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation 2009; 120: 6-8.
8. NOTO N, OKADA T, KARASAWA K et al.: Age-related acceleration of endothelial dysfunction and subclinical atherosclerosis in subjects with coronary artery lesions after Kawasaki disease. Pediatric Cardiol 2009; 30: 262-8.
9. GUPTA-MALHOTRA M, GRUBER D, ABRAHAM SS et al.: Atherosclerosis in survivors of Kawasaki disease. J Pediatr 2009; 155: 572-7.
10. KUROSU H, OGAWA Y, MIYOSHI M et al.: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006; 281: 6120-3.
11. MIRZA MAJ, LARSSON A, LIND L, LARSSON TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-90.
12. GUTIÉRREZ OM, JANUZZI JL, ISAKOVA T et al.: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
13. URAKAWA I, YAMAZAKI Y, SHIMADA T et al.: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-4.
14. SAITO Y, NAKAMURA T, OHYAMA Y et al.: In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000; 276: 767-72.
15. LIU S, TANG W, ZHOU J et al.: Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 2007; 293: 1636-44.
16. DE ROSA G, PARDEO M, RIGANTE D: Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol 2007; 11: 301-8.
17. GUIDUCCI S, RICCI L, ROMANO E et al.: Microparticles and Kawasaki disease: a marker of vascular damage Clin Exp Rheumatol 2011; 29 (Suppl. 64): S121-5.
18. SHIMADA T, KAKITANI M, YAMAZAKI Y et al.: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-8.
19. KURO-O M, MATSUMURA Y, AIZAWA H et al.: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
20. XU MG, MENLN, ZHAO CY et al.: The number and function of circulating endothelial progenitor cells in patients with Kawasaki disease. Eur J Pediatr 2010; 169: 289-96.
21. WANG Y, KURO-O M, SUN Z: Klotho gene delivery suppresses Nox2 expression and attenuates oxidative stress in rat aortic smooth muscle cells via the cAMP-PKA pathway. Aging Cell 2012; 11: 410-7.
22. KUSABA T, OKIGAKI M, MATUI A et al.: Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA 2010; 107: 19308-13.
23. GUTIÉRREZ OM, MANNSTADT M, ISAKOVA T et al.: Fibroblast Growth Factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-92.
24. YU X, IBRAHIMI OA, GOETZ R et al.: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146: 4647-56.